Financials in USD. Standardized financial statements.
A compact view of how JW (Cayman) Therapeutics Co. Ltd turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $276.33M | $158.22M | $173.86M | $145.70M | $30.80M | $0 | $5.48M | $215,000 |
| Revenue Growth? | +74.7% | -9.0% | +19.3% | +373.1% | 0.0% | -100.0% | +2450.2% | 0.0% |
| Cost of Revenue? | $157.42M | $80.90M | $85.64M | $86.95M | $21.75M | $0 | $0 | $0 |
| Gross Profit? | $118.92M | $77.32M | $88.22M | $58.76M | $9.04M | $0 | $5.48M | $215,000 |
| Gross Margin? | +43.0% | +48.9% | +50.7% | +40.3% | +29.4% | 0.0% | +100.0% | +100.0% |
| Operating Expenses? | $360.64M | $536.60M | $877.83M | $914.64M | $768.13M | $440.84M | $639.21M | $112.45M |
| Operating Income? | -$241.73M | -$459.28M | -$789.61M | -$855.88M | -$759.08M | -$440.84M | -$203.52M | -$112.23M |
| EBITDA? | -$161.97M | -$488.74M | -$655.75M | -$752.27M | -$738.70M | -$454.04M | -$194.40M | -$115.96M |
| Income Before Tax | -$537.97M | -$590.62M | -$768.00M | -$846.13M | -$702.33M | -$1.66B | -$633.26M | -$272.62M |
| Income Tax Expense | $2.99M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$540.96M | -$590.62M | -$768.00M | -$846.13M | -$702.33M | -$1.66B | -$633.26M | -$272.62M |
| EPS? | $-1.33 | $-1.43 | $-1.87 | $-2.06 | $-1.76 | $-12.61 | $-2.20 | $-4.19 |
| Diluted EPS? | $-1.33 | $-1.43 | $-1.87 | $-2.06 | $-1.76 | $-12.61 | $-2.20 | $-4.19 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality